All News

2020

January

Media Release / Jan 20, 2020

Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease

Read More
Media Release / Jan 09, 2020

Novartis ligelizumab (QGE031) more effective than Xolair® at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticaria

Read More
Media Release / Jan 06, 2020

Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran

Read More
Media Release / Jan 06, 2020

Novartis completes tender offer for all outstanding shares of The Medicines Company

Read More
2019

December

Media Release / Dec 16, 2019

Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More